Innoviva’s ZEVTERA® & XACDURO® Nominated for 2025 Prix Galien USA Award
Innoviva Specialty Therapeutics Earns Dual Nominations for 2025 Prix Galien USA Best Pharmaceutical Product Award for ZEVTERA® and XACDURO® Innoviva Specialty Therapeutics, a wholly owned subsidiary of Innoviva, Inc. (NASDAQ:…
Pilatus, Roche Partner on First-in-Human PLT012 Liver Cancer Trial
Pilatus Biosciences Launches Clinical Trial Collaboration with Roche to Advance First-in-Human Evaluation of PLT012 in Liver Cancer Pilatus Biosciences, Inc., a biotechnology company focused on developing innovative metabolic checkpoint immunotherapies…
Infinity Bio, AIT Partner to Offer Antibody Reactome Profiling in Europe
Infinity Bio Partners with Austrian Institute of Technology to Deliver Antibody Reactome Profiling Across Europe Infinity Bio, Inc., a pioneering leader in advanced immune system analysis, has announced a strategic…
Response Pharma Reports Positive Phase 2 Results for RDX-002 in Post-GLP-1 Care
Response Pharmaceuticals Announces Positive Phase 2 Results for RDX-002 in Post-GLP-1 Obesity Management Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation therapies for weight management and metabolic…
TriSalus Life Sciences Announces Q2 2025 Financial Results and Affirms Full-Year Outlook
TriSalus Life Sciences Announces Strong Q2 2025 Results, Affirms Full-Year Outlook, and Advances Strategic Focus on Liver-Directed Therapies TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company pioneering innovative delivery…
Bionova Scientific® Launches New Plasmid DNA Facility in Texas to Meet Rising Biopharma Demand
Bionova Scientific® Inaugurates Advanced Plasmid DNA Production Facility in Texas to Support Surging Global Demand for Cell and Gene Therapy Materials Bionova Scientific®, a full-service biologics contract development and manufacturing…
Bayer and Kumquat Biosciences Forge Exclusive Global Partnership to Advance Precision Oncology
Bayer and Kumquat Biosciences Forge Global Exclusive Agreement to Advance Next-Generation KRAS G12D Inhibitor in Precision Oncology Bayer AG, a global life sciences company with a growing presence in oncology,…
Newron Starts Phase III ENIGMA-TRS Trial of Evenamide for Treatment-Resistant Schizophrenia
Newron Pharmaceuticals Launches Pivotal Phase III ENIGMA-TRS Program, Randomizing First Patients to Evaluate Evenamide as an Add-On Therapy in Treatment-Resistant Schizophrenia Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5), a biopharmaceutical…
PureTech Launches Celea Therapeutics to Revolutionize Respiratory Disease Treatment
PureTech Health Launches Celea Therapeutics to Transform the Treatment Landscape for Respiratory Diseases PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company committed to…
PADCEV + KEYTRUDA Boost Survival in Select Bladder Cancer Patients Pre- and Post-Surgery
Pfizer and Astellas Announce Landmark Phase 3 Results for PADCEV™ Plus KEYTRUDA™ in Muscle-Invasive Bladder Cancer, Marking Potential Paradigm Shift in Treatment for Cisplatin-Ineligible Patients Pfizer Inc. (NYSE: PFE) and…
Quince Therapeutics Announces Q2 2025 Financial Results and Corporate Update
Quince Therapeutics Announces Major Clinical and Corporate Milestones Alongside Q2 2025 Financial Results Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to harnessing a patient’s own biology for…
Enanta Pharmaceuticals Q3 FY2025 Financial Results
Enanta Pharmaceuticals Reports Fiscal Third Quarter 2025 Results and Provides Pipeline Progress Update Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to the discovery and development of small…